Welcome to our dedicated page for DSS SEC filings (Ticker: DSS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DSS, Inc. filings document the company's public-company reporting, securities registrations, capital structure, and material events for a New York corporation with common stock listed on NYSE American. Registration statements cover common-stock offering mechanics, issuer classification, and Securities Act disclosure for financing activity.
Form 8-K filings report shareholder voting results, director elections, auditor changes, material agreements, debt-conversion arrangements involving Impact Biomedical, and other capital-structure matters. The filing record also includes audit and going-concern disclosure tied to annual reporting, along with governance and operating-result categories relevant to DSS's diversified segments.
DSS, Inc. reports weaker results for the quarter and six months ended June 30, 2026. Total revenue for the quarter was $3.6 million versus $5.3 million a year earlier, and $7.9 million for the six-month period versus $10.2 million. The company recorded an operating loss of $3.8 million for the quarter and $9.3 million year-to-date, compared with $3.4 million and $7.2 million in the prior-year periods.
Net loss attributable to common stockholders widened to $4.8 million for the quarter and $10.4 million for the six months, with basic and diluted loss per share of $0.48 and $1.06, respectively. Cash and cash equivalents declined to $4.1 million, marketable securities to $2.8 million, and current assets to $9.4 million against current liabilities of $49.2 million, resulting in a reported negative working capital position of about $39.9 million. Management discloses that these conditions raise substantial doubt about the company’s ability to continue as a going concern and outlines plans relying on asset sales, additional financing, and cost reductions.
The balance sheet reflects significant debt, including approximately $38.5 million under a LifeCare real estate loan that is in default and past due. DSS also reports large credit loss reserves on notes receivable and continues to engage in related-party financing and investment transactions, including an equity method investment in True Partners Capital Holding Limited and convertible financing arrangements with Alset-affiliated entities. As of August 5, 2026, there were 10,042,518 common shares outstanding.
DSS, INC. reported an indirect restructuring-type transaction involving entities associated with director and ten percent owner Chan Heng Fai Ambrose. Alset International Limited holds a $2,450,000 Convertible Promissory Note that became convertible into common stock at $0.74 per share on June 3, 2026. On March 26, 2026, Alset International Limited also received common stock purchase warrants to buy up to 16,554,055 DSS common shares at an exercise price of $0.93 per share, expiring on March 26, 2031. The filing notes these positions as indirectly beneficially owned through entities controlled by Mr. Chan.
DSS, Inc. received an updated ownership report showing that Heng Fai Ambrose Chan and his affiliated entities now beneficially own 26,464,246 shares and related derivatives, representing 86.8% of DSS common stock. This percentage is based on 10,042,518 shares outstanding as of July 9, 2026.
The position includes a $2,450,000 convertible promissory note issued to Alset International Limited, initially convertible at $0.74 per share, and common stock purchase warrants to buy up to 16,554,055 shares at $0.93 per share expiring on March 26, 2031. These instruments give the Alset group significant additional potential ownership beyond current common shares.
DSS, Inc. entered into a material definitive financing agreement with Alset, Inc., under which Alset will loan DSS $1,000,000 in exchange for a convertible promissory note and stock warrants.
The note carries simple interest of 3% per year and matures five years from issuance. Alset may convert principal and accrued interest into DSS common stock at $0.45 per share. Separately, Alset receives warrants to purchase up to 17,777,776 DSS shares at an exercise price of $0.50 per share, expiring three years from issuance.
The deal is a related party transaction because DSS and Alset are under common control of Chan Heng Fai and share overlapping directors. The agreements were approved by DSS’s board and, where applicable, its audit committee, with interested directors recusing themselves.
DSS, Inc. reported a larger net loss for the quarter ended March 31, 2026 and raised substantial doubt about its ability to continue as a going concern. Revenue fell to $4.33 million from $4.95 million a year earlier, while cost of revenue and higher selling, general and administrative expenses drove an operating loss of $5.49 million versus $3.73 million in 2025.
Net loss widened to $6.35 million, or $0.60 per share, compared with $5.30 million, or $0.55 per share. Cash and cash equivalents declined to $4.94 million, and operating and investing activities used cash. DSS carries significant debt, including a large medical-facility loan in default, and disclosed substantial doubt about continuing as a going concern despite recognizing an $8.52 million related-party convertible bond investment that lifted total assets and stockholders’ equity.
DSS, Inc. is furnishing a definitive Information Statement to notify holders that holders of a majority of voting stock approved corporate actions by written consent taken March 18, 2026 and effective no sooner than 20 days after mailing. The Record Date for notice was April 22, 2026, when 10,042,518 shares of Common Stock were outstanding.
Action 1 (Issuance Proposal): the Company entered an SPA dated March 26, 2026 under which Alset International Limited will loan $2,450,000 in exchange for a convertible note and warrants to purchase 16,554,055 shares. The note bears 3% simple interest, converts at $0.74 per share, matures in five years, and the warrants have an exercise price of $0.93 and five-year term. After conversion and exercise as described, Alset International Limited would beneficially own 20,933,175 shares, approximately 70% of outstanding common stock.
DSS, Inc. plans a primary offering of up to 8,333,333 shares of common stock and up to 8,333,333 pre-funded warrants, plus 8,333,333 shares underlying those warrants, for gross proceeds of $8,000,000 at an assumed price of $0.96 per share. This “reasonable best efforts” deal is led by Aegis Capital as placement agent, which will earn an 8% cash fee and expense allowance. Pre-funded warrants are priced at $0.95999 with a de minimis $0.00001 exercise price and include 4.99% (or 9.99% at holder election) ownership caps. Shares outstanding would rise from 10,042,518 to 18,375,851 if all shares are sold and no pre-funded warrants are issued. DSS expects net proceeds of about $7.05 million at full take-up, earmarked mainly for working capital and general corporate purposes. The filing highlights substantial existing secured and convertible debt, concentration of revenue in one major customer, internal control weaknesses, NYSE American listing risk and significant potential dilution from existing convertibles and warrants.
DSS, Inc. furnished an Information Statement notifying holders that majority stockholders approved corporate actions by written consent; the actions will be effective no sooner than 20 days after mailing of a definitive Information Statement.
The filing discloses an Issuance Proposal: a March 26, 2026 securities purchase agreement with Alset International Limited for a $2,450,000 loan in exchange for a convertible promissory note convertible at $0.74 per share (five-year maturity) and warrants to purchase 16,554,055 common shares at an exercise price of $0.93. The transaction requires shareholder approval under NYSE Section 312.03 for issuance in excess of 19.99%.
DSS, Inc. is registering up to 8,333,333 shares of common stock and up to 8,333,333 pre-funded warrants, targeting gross proceeds of $8,000,000 at an assumed price of $0.96 per share. An additional 8,333,333 shares of common stock are registered for issuance upon exercise of the pre-funded warrants.
The offering is on a reasonable best efforts basis through Aegis Capital as placement agent, with no minimum raise. Net proceeds are expected to be about $7.05M if fully sold, earmarked mainly for working capital and general corporate purposes. Shares outstanding would increase from 10,042,518 to 18,375,851, resulting in material dilution to new investors based on a net tangible book value moving from approximately ($1.11) to ($0.17) per share.